Mayo Clinic receives $15 million to launch innovative neuroscience research program

September 30, 2005

ROCHESTER, Minn. -- Mayo Clinic has received $15 million for research that will accelerate the testing of promising therapies for patients with diseases of the nervous system. This is the first major gift to Mayo Clinic's Discovery, Innovation and Investment Fund and will help launch an intense program of research focused clearly on patient care. Of this gift, $8 million will be used to test treatment approaches that have already been shown by discovery research to be ready for human trials; $3 million has been dedicated to basic research. Examples of neuroscience research include Alzheimer's disease, multiple sclerosis, Parkinson's disease, stroke and spinal cord injury.

The gift, from Eugene and Marcia Applebaum of Bloomfield, Mich., also includes $4 million to endow two Mayo Medical School professorships; this amount will be matched by Mayo Clinic. "People want to know there is hope around the corner," says Mr. Applebaum. "Translational research is the seventh inning of research and there often isn't enough funding at that point to move the research findings quickly to the patient. And, there needs to be a strong educational component to all of this."

Rated the nation's number one neuroscience research center by U.S. News and World Report, Mayo Clinic's translational research is unique. "We are sincerely grateful for the Applebaums' generosity and for their significant interest in research," says Denis Cortese, M.D., President and CEO of Mayo Clinic and the chair of the Discovery Translation Investment Committee. "This gift will support physicians who can take the basic research discoveries of their colleagues and figure out how to apply that knowledge to the treatment of their patients. The Applebaum funding will help Mayo Clinic narrow the gap between basic science and patient care because Mayo Clinic marries the lab and the clinic in a way no other organization does. This is innovation at its best."

Through a peer-reviewed process that recognizes top opportunities to translate scientific discoveries into patient care, Mayo Clinic researchers from a variety of disciplines will be eligible to apply for a grant from the Investment Fund. In addition to this important gift from Mr. and Mrs. Applebaum, Mayo will dedicate to this fund a portion of its own revenues, generated through the commercialization of Mayo-developed technologies, to further support this research.

"Typically it takes many years for a discovery to move out of the lab and into the clinical setting," explains John Noseworthy, M.D., a neurologist and chair of the Neuroscience Research Initiative. "We believe this additional funding will help accelerate that process by giving support to researchers who are working directly with patients. These physicians can use the knowledge they gain from day-to-day interaction with their patients to figure out how a discovery may eventually have application to patient care. This is a very exciting time for research and for the future care of our patients."

"At Mayo Clinic, we see our work as having three component parts: practice, education and research," says Hugh Smith, M.D., chair of the Mayo Clinic Rochester Board of Governors. "While the process of research is lengthy, it strengthens our medical practice every day because the presence of research creates a spirit of inquiry that keeps people asking questions and searching for answers. And sharing this information through formal and informal education opportunities means everyone here can benefit from it. We truly value this partnership the Applebaums have helped make possible."

The Applebaums are long time patients and benefactors of Mayo Clinic. Mr. Applebaum is the president of Arbor Investments Group. A pharmacist, he founded Arbor Drugs in 1974, and it grew to be the eighth largest drugstore chain in the nation. In 1998 it was acquired by Rhode Island-based CVS, a "Fortune 100" organization and the nation's largest drugstore chain. Applebaum sits on that company's board.
To obtain the latest news releases from Mayo Clinic, go to ( is available as a resource for your health stories.

Mayo Clinic

Related Nervous System Articles from Brightsurf:

Chikungunya may affect central nervous system as well as joints and lungs
Investigation conducted by international group of researchers showed that chikungunya virus can cause neurological infections.

Glial cells play an active role in the nervous system
Researchers at M√ľnster University, Germany, have discovered that glial cells - one of the main components of the brain -not only control the speed of nerve conduction, but also influence the precision of signal transduction in the brain.

Protein produced by the nervous system may help treatments for inflammatory diseases
A Rutgers-led team discover a protein produced by nervous system may be key to treating inflammatory diseases like asthma, allergies, chronic fibrosis and chronic obstructive pulmonary disease (COPD)

COVID-19 may attack patients' central nervous system
''There may be more central nervous system penetration of the virus than we think based on the prevalence of olfaction-associated depressed mood and anxiety and this really opens up doors for future investigations to look at how the virus may interact with the central nervous system,'' explains Ahmad Sedaghat, MD, PhD.

Lifting weights makes your nervous system stronger, too
Gym-goers may get frustrated when they don't see results from weightlifting right away, but their efforts are not in vain: the first few weeks of training strengthen the nervous system, not muscles.

COVID-19 threatens the entire nervous system
A new review of neurological symptoms of COVID-19 patients in current scientific literature reveals the disease poses a global threat to the entire nervous system.

Fewer scars in the central nervous system
Researchers have discovered the influence of the coagulation factor fibrinogen on the damaged brain.

Polymerized estrogen shown to protect nervous system cells
In research published today in Nature Communications, an interdisciplinary team from Rensselaer Polytechnic Institute demonstrated how estrogen -- a natural hormone produced in the body -- can be polymerized into a slow-releasing biomaterial and applied to nervous system cells to protect those cells and even promote regeneration.

Discovery concerning the nervous system overturns a previous theory
It appears that when our nervous system is developing, only the most viable neurons survive, while immature neurons are weeded out and die.

Autonomic nervous system appears to function well regardless of mode of childbirth
'In a low-risk group of babies born full-term, the autonomic nervous system and cortical systems appear to function well regardless of whether infants were exposed to labor prior to birth,' says Sarah B.

Read More: Nervous System News and Nervous System Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to